文献速递肾移植

肾移植后复发性非典型溶血性尿毒症综合征患者的依库珠单抗挽救治疗

Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation.
PubMed 文献 · Kidney Int Rep · 2023-01-19

荷兰自2016年起对非典型溶血性尿毒症综合征(aHUS)肾移植患者不进行依库珠单抗预防,仅在移植后复发时使用依库珠单抗治疗。CUREiHUS研究纳入15例疑似复发的患者,中位随访29个月,14例eGFR改善或稳定,但6例eGFR<30 ml/min/1.73 m2,其中3例移植肾丢失。不预防下总体复发率为23%。

要点

  • 肾移植后aHUS复发呈双峰分布:早期中位3个月,晚期中位46个月。
  • 晚期复发中5例仅表现为eGFR缓慢下降,无系统性TMA证据。
  • 依库珠单抗挽救治疗使14例eGFR改善或稳定,但部分患者肾功能不可逆丧失。

核心结论

  • 移植后aHUS复发的挽救治疗有效,但部分患者仍出现不可逆的肾功能丧失,可能由诊断和治疗延迟和/或过于激进地停用依库珠单抗所致。
  • 医生应意识到aHUS复发可在无系统性TMA证据的情况下出现。

研究设计与样本

  • CUREiHUS研究为前瞻性监测研究,纳入2016年1月至2020年10月在荷兰接受肾移植后疑似aHUS复发并接受依库珠单抗治疗的患者15例(12例女性,3例男性;中位年龄42岁,范围24-66岁)。
  • 总体复发率在Radboud大学医学中心进行前瞻性监测。

主要发现

  • 复发时间呈双峰分布:7例早期复发(中位3个月,范围0.3-8.8个月),表现为快速eGFR下降和TMA实验室证据;8例晚期复发(中位46个月,范围18-69个月),其中仅3例有系统性TMA,5例表现为eGFR缓慢下降而无系统性TMA。
  • 依库珠单抗治疗使14例患者eGFR改善或稳定。
  • 7例尝试停用依库珠单抗,仅3例成功。
  • 随访结束时(依库珠单抗开始后中位29个月,范围3-54个月),6例eGFR<30 ml/min/1.73 m2,其中3例移植肾丢失。
  • 不进行依库珠单抗预防的情况下,总体aHUS复发率为23%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Since 2016, kidney transplantation in patients with atypical hemolytic uremic syndrome (aHUS) in the Netherlands is performed without eculizumab prophylaxis. Eculizumab is given in case of posttransplant aHUS recurrence. Eculizumab therapy is monitored in the CUREiHUS study. METHODS: All participating kidney transplant patients who received eculizumab therapy for a suspected posttransplant aHUS recurrence were evaluated. Overall recurrence rate was monitored prospectively at Radboud University Medical Center. RESULTS: In the period from January 2016 until October 2020, we included 15 (12 females, 3 males; median age 42 years, range 24-66 years) patients with suspected aHUS recurrence after kidney transplantation in this study. The time interval to recurrence showed a bimodal distribution. Seven patients presented early after transplantation (median 3 months, range 0.3-8.8 months), with typical aHUS features: rapid loss of estimated glomerular filtration rate (eGFR) and laboratory signs of thrombotic microangiopathy (TMA). Eight patients presented late (median 46 months, range 18-69 months) after transplantation. Of these, only 3 patients had systemic TMA, whereas 5 patients presented with slowly deteriorating eGFR without systemic TMA. Treatment with eculizumab resulted in improvement or stabilization of eGFR in 14 patients. Eculizumab discontinuation was tried in 7 patients; however, it was successful only in 3. At the end of the follow-up (median 29 months, range 3-54 months after start of eculizumab), 6 patients had eGFR <30 ml/min per 1.73 m2. Graft loss had occurred in 3 of them. Overall, aHUS recurrence rate without eculizumab prophylaxis was 23%. CONCLUSIONS: Rescue treatment of posttransplant aHUS recurrence is effective; however, some patients suffer from irreversible loss of kidney function, likely caused by delayed diagnosis and treatment and/or too aggressive discontinuation of eculizumab. Physicians should be aware that recurrence of aHUS can present without evidence of systemic TMA.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Duineveld C, Bouwmeester RN, Wijnsma KL, et al. Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation. Kidney Int Rep. 2023. PMID: 37069997. doi:10.1016/j.ekir.2023.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。